Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-15
2009-08-04
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S316000, C514S318000, C514S319000, C514S320000, C514S321000, C514S322000, C546S186000, C546S191000, C546S194000, C546S196000, C546S198000, C546S199000, C546S248000
Reexamination Certificate
active
07569586
ABSTRACT:
This invention provides compounds of formula I:wherein R1, R2, R3, R4,R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
REFERENCES:
patent: 6433027 (2002-08-01), Bozung et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 6576793 (2003-06-01), Moran et al.
patent: 6593497 (2003-07-01), Choi et al.
patent: 6635764 (2003-10-01), Mammen et al.
patent: 6653323 (2003-11-01), Moran et al.
patent: 6670376 (2003-12-01), Moran et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 6713651 (2004-03-01), Moran et al.
patent: 6747043 (2004-06-01), Moran et al.
patent: 2004/0029919 (2004-02-01), Mammen et al.
patent: 2004/0167167 (2004-08-01), Mammen et al.
patent: 2004/0209860 (2004-10-01), Mammen et al.
patent: 2004/0209915 (2004-10-01), Mammen et al.
patent: 2005/0113417 (2005-05-01), Mammen et al.
patent: 2005/0182092 (2005-08-01), Chao et al.
patent: 686 869 (1996-07-01), None
patent: 0 286 242 (1988-10-01), None
patent: 0 747 355 (1996-12-01), None
patent: WO 93/20071 (1993-10-01), None
patent: WO 99/64031 (1999-12-01), None
patent: WO 01/42212 (2001-06-01), None
patent: WO 01/42213 (2001-06-01), None
patent: WO 02/070490 (2002-09-01), None
patent: WO 02/076933 (2002-10-01), None
patent: WO 03/024439 (2003-03-01), None
patent: WO 03/042164 (2003-05-01), None
patent: WO 03/072539 (2003-09-01), None
patent: WO 2004/012684 (2004-02-01), None
patent: WO 2004/074246 (2004-09-01), None
patent: WO 2004/074276 (2004-09-01), None
Naito et al., “Selective Muscarinic Antagonists. II. Synthesis and Antimuscarinic Properties of Biphenylcarbamate Derivatives”, Chem. Pharm. Bull, vol. 46, No. 8, pp. 1286-1294 (1998).
Reitz et al., “Conjugates of Catecholamines. 6. Synthesis and Beta-Adrenergic Activity N-(Hydrocyalkyl)catecholamine Derivatives”, Journal of Medicinal Chemistry, vol. 28, No. 5, pp. 642-647 (1985).
Hughes Adam
Ji Yu-Hua
Mammen Mathai
Mischki Trevor
Andres Janet L
Gallis David E
Hagenah Jeffrey A.
Theravance Inc.
LandOfFree
Compounds having β 2 adrenergic receptor agonist and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having β 2 adrenergic receptor agonist and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having β 2 adrenergic receptor agonist and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4066930